NZ600478A - Beta-carbolines for use in the treatment of hearing loss and vertigo - Google Patents

Beta-carbolines for use in the treatment of hearing loss and vertigo

Info

Publication number
NZ600478A
NZ600478A NZ600478A NZ60047810A NZ600478A NZ 600478 A NZ600478 A NZ 600478A NZ 600478 A NZ600478 A NZ 600478A NZ 60047810 A NZ60047810 A NZ 60047810A NZ 600478 A NZ600478 A NZ 600478A
Authority
NZ
New Zealand
Prior art keywords
carboline
vertigo
methyl
trauma
carbolines
Prior art date
Application number
NZ600478A
Other languages
English (en)
Inventor
Hans Rommelspacher
Original Assignee
Audiocure Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Audiocure Pharma Gmbh filed Critical Audiocure Pharma Gmbh
Publication of NZ600478A publication Critical patent/NZ600478A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ600478A 2009-12-28 2010-12-28 Beta-carbolines for use in the treatment of hearing loss and vertigo NZ600478A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009060811 2009-12-28
US28239510P 2010-02-02 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (1)

Publication Number Publication Date
NZ600478A true NZ600478A (en) 2013-10-25

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600478A NZ600478A (en) 2009-12-28 2010-12-28 Beta-carbolines for use in the treatment of hearing loss and vertigo

Country Status (17)

Country Link
US (1) US9107914B2 (enExample)
EP (1) EP2519238B1 (enExample)
JP (1) JP5627705B2 (enExample)
KR (1) KR20120098855A (enExample)
CN (1) CN102844029A (enExample)
AU (1) AU2010338669A1 (enExample)
BR (1) BR112012015967B1 (enExample)
CA (1) CA2785233C (enExample)
DE (1) DE112010005017A5 (enExample)
IL (1) IL220661A (enExample)
IN (1) IN2012DN05066A (enExample)
MX (1) MX2012007678A (enExample)
NZ (1) NZ600478A (enExample)
RU (1) RU2012132429A (enExample)
SG (1) SG181599A1 (enExample)
WO (1) WO2011079841A1 (enExample)
ZA (1) ZA201204476B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968284T3 (pl) * 2013-03-14 2021-09-27 Osteoqc Inc. Pochodne alkilo-amino harminy wspierające wzrost kości
PT3702443T (pt) 2013-03-14 2022-02-17 Massachusetts Inst Technology Composições e métodos para expansão e cultura de células estaminais epiteliais
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
SG10201910821XA (en) 2016-12-30 2020-01-30 Frequency Therapeutics Inc 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CA3108714A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
US11903949B2 (en) 2018-08-14 2024-02-20 Ossifi Therapeutics Llc Fluoro beta-carboline compounds
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
KR102899320B1 (ko) * 2018-09-12 2025-12-12 호 이어 인스티튜트 인공 와우 수술에 따른 난청의 치료 방법
EP3772515A1 (en) * 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
RU2233841C2 (ru) * 1998-06-12 2004-08-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Бета-карболиновые соединения, фармацевтические композиции на их основе и способы связывания, достижения агонистического/антагонистического эффекта
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US20050101623A1 (en) * 2003-07-23 2005-05-12 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
WO2011079841A1 (de) 2011-07-07
BR112012015967A2 (pt) 2016-04-19
EP2519238B1 (de) 2014-08-13
MX2012007678A (es) 2012-09-12
RU2012132429A (ru) 2014-02-10
CA2785233A1 (en) 2011-06-07
SG181599A1 (en) 2012-07-30
KR20120098855A (ko) 2012-09-05
US20130028958A1 (en) 2013-01-31
ZA201204476B (en) 2014-01-29
CA2785233C (en) 2018-10-09
JP5627705B2 (ja) 2014-11-19
AU2010338669A1 (en) 2012-06-21
IL220661A (en) 2016-03-31
IN2012DN05066A (enExample) 2015-10-09
DE112010005017A5 (de) 2012-10-04
EP2519238A1 (de) 2012-11-07
BR112012015967B1 (pt) 2019-08-27
US9107914B2 (en) 2015-08-18
CN102844029A (zh) 2012-12-26
JP2013515752A (ja) 2013-05-09
IL220661A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
NZ600478A (en) Beta-carbolines for use in the treatment of hearing loss and vertigo
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2010002617A (es) Implantes lagrimales y metodos relacionados.
JO3032B1 (ar) مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
IL212113A (en) A device for the implantation of a drug for glaucoma treatment
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
UA115320C2 (uk) Інгібітори кінази
UA105781C2 (uk) Низькомолекулярне полісульфатоване похідне гіалуронової кислоти і лікарський засіб, який його містить
PH12012501021A1 (en) Indole compound and pharmaceutical use thereof
NZ602510A (en) Treatment of lupus nephritis using laquinimod
MX2011011109A (es) Formulaciones orales de bendamustina.
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2012000136A (es) Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ597030A (en) Method for treatment of diseases
WO2010132352A3 (en) Spiro compounds and their use as therapeutic agents
MX2010010455A (es) Formas solidas de un compuesto fosfoindol anti-vih.
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
WO2007035121A3 (en) Isoflavones for treating mucopolysaccharidoses
MX356814B (es) Métodos y composiciones para neuroprotección.
EP4494704A3 (en) Use of cyclic amide derivatives to treat sleep disorders
MX2009005503A (es) Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.
RU2010135224A (ru) Способ хирургического лечения макулярного отека после факоэмульсификации катаракты
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2015 BY PAVIS EG

Effective date: 20141212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2016 BY PAVIS EG

Effective date: 20151210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2017 BY PAVIS EG

Effective date: 20161219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2018 BY PAVIS GMBH

Effective date: 20171215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2019 BY PAVIS GMBH

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2020 BY PAVIS GMBH

Effective date: 20191220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2021 BY PAVIS PAYMENTS GMBH

Effective date: 20201223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2022 BY PAVIS GMBH

Effective date: 20211216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2023 BY PAVIS PAYMENTS GMBH

Effective date: 20221221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20231214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2025 BY PAVIS PAYMENT GMBH

Effective date: 20241216